A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors
cMET-dysregulated Advanced Solid Tumors
DRUG: INC280|DRUG: Midazolam|DRUG: Caffeine
AUClast of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameters, Up to 72 hours post midazolam and caffeine dose|AUCinf of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameter, Up to 72 hours post midazolam and caffeine dose|Lambda_z of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameter, Up to 72 hours post midazolam and caffeine dose|Cmax of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameter, Up to 72 hours post midazolam and caffeine dose|Tmax of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameter, Up to 72 hours post midazolam and caffeine dose|T1/2 of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameter, Up to 72 hours post midazolam and caffeine dose|CL/F of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameter, Up to 72 hours post midazolam and caffeine dose|Vz/F of midazolam and caffeine, midazolam and caffeine pharmacokinetic parameter, Up to 72 hours post midazolam and caffeine dose
Adverse events based on the CTCAE v4.03 grade (severity) and other safety data (e.g.,ECG, vital signs, laboratory results), To assess safety and tolerability of INC280 in patients with cMET-dysregulated advanced solid tumors, From consent to 30 days post last dose|Overall response rate of patients treated with INC280, Overall response rate is defined as Complete Response and Partial Response calculated per RECIST 1.1, per investigator assessment, Baseline, every 6 weeks|Disease control rate of patients treated with INC280, Disease control rate is defined as calculated as the proportion of patients with best overall response of Complete Response, Partial Response, or Stable Disease calculated per RECIST 1.1, per investigator assessment, Baseline, every 6 weeks
Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors